Estadísticas

 array:23 [
  "pii" => "S1889183713700229"
  "issn" => "18891837"
  "doi" => "10.1016/S1889-1837(13)70022-9"
  "estado" => "S300"
  "fechaPublicacion" => "2013-03-01"
  "aid" => "70022"
  "copyright" => "Sociedad Española de Hipertension-Liga Española para la Lucha de la Hipertensión Arterial (SEH-LELHA)"
  "copyrightAnyo" => "2013"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Hipertens Riesgo Vasc. 2013;30 Supl 2:20-9"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 77548
    "formatos" => array:3 [
      "EPUB" => 8
      "HTML" => 5476
      "PDF" => 72064
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S1889183713700230"
    "issn" => "18891837"
    "doi" => "10.1016/S1889-1837(13)70023-0"
    "estado" => "S300"
    "fechaPublicacion" => "2013-03-01"
    "aid" => "70023"
    "copyright" => "Sociedad Española de Hipertension-Liga Española para la Lucha de la Hipertensión Arterial (SEH-LELHA)"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Hipertens Riesgo Vasc. 2013;30 Supl 2:30-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 5310
      "formatos" => array:3 [
        "EPUB" => 7
        "HTML" => 915
        "PDF" => 4388
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Evoluci&#243;n en el manejo de los f&#225;rmacos antihipertensivos&#58; del diamante al tri&#225;ngulo</span>"
      "titulo" => "Diferencias y similitudes entre inhibidores de la enzima de conversi&#243;n de la angiotensina y antagonistas de los receptores de la angiotensina II"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "30"
          "paginaFinal" => "38"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Differences and similarities between angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46;A&#46; Garc&#237;a Donaire"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "J&#46;A&#46;"
              "apellidos" => "Garc&#237;a Donaire"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1889183713700230?idApp=UINPBA00004N"
    "url" => "/18891837/00000030000000S2/v3_201304200327/S1889183713700230/v3_201304200327/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S1889183713700217"
    "issn" => "18891837"
    "doi" => "10.1016/S1889-1837(13)70021-7"
    "estado" => "S300"
    "fechaPublicacion" => "2013-03-01"
    "aid" => "70021"
    "copyright" => "Sociedad Espa&#241;ola de Hipertension&#45;Liga Espa&#241;ola para la Lucha de la Hipertensi&#243;n Arterial &#40;SEH&#45;LELHA&#41;"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Hipertens Riesgo Vasc. 2013;30 Supl 2:13-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 30769
      "formatos" => array:3 [
        "EPUB" => 10
        "HTML" => 1871
        "PDF" => 28888
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Evoluci&#243;n en el manejo de los f&#225;rmacos antihipertensivos&#58; del diamante al tri&#225;ngulo</span>"
      "titulo" => "Diferencias y similitudes entre diur&#233;ticos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "13"
          "paginaFinal" => "19"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Differences and similarities among diuretics"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#46;J&#46; Morales-Olivas"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "Morales-Olivas"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1889183713700217?idApp=UINPBA00004N"
    "url" => "/18891837/00000030000000S2/v3_201304200327/S1889183713700217/v3_201304200327/es/main.assets"
  ]
  "es" => array:12 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Evoluci&#243;n en el manejo de los f&#225;rmacos antihipertensivos&#58; del diamante al tri&#225;ngulo</span>"
    "titulo" => "Diferencias y similitudes entre los bloqueadores de los receptores del calcio &#40;antagonistas del calcio&#41;"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "20"
        "paginaFinal" => "29"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "D&#46; Real de As&#250;a, C&#46; Su&#225;rez"
        "autores" => array:2 [
          0 => array:2 [
            "nombre" => "D&#46;"
            "apellidos" => "Real de As&#250;a"
          ]
          1 => array:4 [
            "nombre" => "C&#46;"
            "apellidos" => "Su&#225;rez"
            "email" => array:1 [
              0 => "csuarez&#46;hlpr&#64;salud&#46;madrid&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">¿</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Unidad de Hipertensi&#243;n Arterial y Riesgo Vascular&#44; Servicio de Medicina Interna&#44; Hospital Universitario de la Princesa&#44; Madrid&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Differences and similarities among calcium-channel blockers"
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec78191"
          "palabras" => array:5 [
            0 => "Antagonistas del calcio"
            1 => "Hipertensi&#243;n arterial"
            2 => "Hipertrofia ventricular izquierda"
            3 => "Morbimortalidad"
            4 => "Edema"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec78192"
          "palabras" => array:5 [
            0 => "Calcium-channel blockers"
            1 => "Hypertension"
            2 => "Left ventricular hypertrophy"
            3 => "Morbidity and mortality"
            4 => "Edema"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Los antagonistas del calcio &#40;AC&#41; son f&#225;rmacos de primera l&#237;nea para el tratamiento de la hipertensi&#243;n arterial&#46; Multiples estudios de morbimortalidad demuestran que son f&#225;rmacos con una excelente capacidad hipotensora&#44; capaces de revertir lesiones subcl&#237;nicas de &#243;rganos diana como la hipertrofia ventricular izquierda o la microalbuminuria&#46; Si bien la mayor&#237;a de los ensayos se han realizado con dihidropirid&#237;nicos&#44; particularmente con amlodipino&#44; existen tambi&#233;n estudios de morbimortalidad que posicionan a los AC no dihidropirid&#237;nicos&#44; en concreto a verapamilo&#44; como f&#225;rmacos de primera l&#237;nea&#46; Los AC no dihidropirid&#237;nicos aportan una serie de ventajas adicionales como su efecto antianginoso por vasodilataci&#243;n coronaria&#44; su efecto antiarr&#237;tmico cronotropo negativo&#44; con reducci&#243;n de la variabilidad de la frecuencia card&#237;aca&#44; y su menor incidencia de edemas perif&#233;ricos&#46; Finalmente&#44; su amplia potencialidad de combinaci&#243;n con otros grupos farmacol&#243;gicos de primera l&#237;nea en el tratamiento de la hipertensi&#243;n arterial convierte a los AC en f&#225;rmacos particularmente atractivos&#46;</p>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Calcium-channel blockers &#40;CCB&#41; are first-line treatment options for hypertension&#46; Multiple studies have demonstrated their excellent blood-pressure-lowering activity&#44; and a wide number of morbidity and mortality studies have shown these drugs to be able to revert subclinical organ damage such as left ventricular hypertrophy or microalbuminuria&#46; Although most studies have been carried out with the dihydropyridine &#40;DHP&#41;&#44; amlodipine&#44; several studies of morbidity and mortality support the use the non-DHP&#44; verapamil&#44; as a first-line agent&#46; Non-DHPs provide a series of advantages such as their potent coronary vasodilator effect&#44; an antiarrhythmic effect based on their negative chronotropic and inotropic properties&#44; and a lower incidence of peripheral edema&#46; Finally&#44; their wide possibilities for combination with other first-line agents&#44; such as renin-angiotensin system blockers&#44; make calcium-channel blockers especially attractive&#46;</p>"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/18891837/00000030000000S2/v3_201304200327/S1889183713700229/v3_201304200327/es/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/18891837/00000030000000S2/v3_201304200327/S1889183713700229/v3_201304200327/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1889183713700229?idApp=UINPBA00004N"
]